["[Tab] Consolidated Statements of Operations for Eli Lilly and Company\n\n[Time]: December 31, 2023 [SEP]\n[row 0]: Revenue [SEP]\n[row 1]: Total Revenue | $34,124.1 [SEP]\n[row 2]: Cost of sales | $7,082.2 [SEP]\n[row 3]: Research and development | $9,313.4 [SEP]\n[row 4]: Marketing, selling, and administrative | $7,403.1 [SEP]\n[row 5]: Acquired in-process research and development | $3,799.8 [SEP]\n[row 6]: Asset impairment, restructuring, and other special charges | $67.7 [SEP]\n[row 7]: Other\u2014net, (income) expense | $(96.7) [SEP]\n[row 8]: Income before income taxes | $6,554.6 [SEP]\n[row 9]: Income taxes | $1,314.2 [SEP]\n[row 10]: Net income | $5,240.4 [SEP]\n[row 11]: Earnings per share | $5.82 | Basic [SEP]\n[row 12]: Earnings per share | $5.80 | Diluted [SEP]\n[row 13]: Shares used in calculation of earnings per share | 900,181 | Basic [SEP]\n[row 14]: Shares used in calculation of earnings per share | 903,284 | Diluted [SEP]\n\n[Time]: December 31, 2022 [SEP]\n[row 0]: Revenue [SEP]\n[row 1]: Total Revenue | $28,541.4 [SEP]\n[row 2]: Cost of sales | $6,629.8 [SEP]\n[row 3]: Research and development | $7,190.8 [SEP]\n[row 4]: Marketing, selling, and administrative | $6,440.4 [SEP]\n[row 5]: Acquired in-process research and development | $908.5 [SEP]\n[row 6]: Asset impairment, restructuring, and other special charges | $244.6 [SEP]\n[row 7]: Other\u2014net, (income) expense | $(320.9) [SEP]\n[row 8]: Income before income taxes | $6,806.4 [SEP]\n[row 9]: Income taxes | $561.6 [SEP]\n[row 10]: Net income | $6,244.8 [SEP]\n[row 11]: Earnings per share | $6.93 | Basic [SEP]\n[row 12]: Earnings per share | $6.90 | Diluted [SEP]\n[row 13]: Shares used in calculation of earnings per share | 901,736 | Basic [SEP]\n[row 14]: Shares used in calculation of earnings per share | 904,619 | Diluted [SEP]\n\n[Time]: December 31, 2021 [SEP]\n[row 0]: Revenue [SEP]\n[row 1]: Total Revenue | $28,318.4 [SEP]\n[row 2]: Cost of sales | $7,312.8 [SEP]\n[row 3]: Research and development | $6,930.7 [SEP]\n[row 4]: Marketing, selling, and administrative | $6,431.6 [SEP]\n[row 5]: Acquired in-process research and development | $970.1 [SEP]\n[row 6]: Asset impairment, restructuring, and other special charges | $316.1 [SEP]\n[row 7]: Other\u2014net, (income) expense | $316.1 [SEP]\n[row 8]: Income before income taxes | $6,155.5 [SEP]\n[row 9]: Income taxes | $573.8 [SEP]\n[row 10]: Net income | $5,581.7 [SEP]\n[row 11]: Earnings per share | $6.15 | Basic [SEP]\n[row 12]: Earnings per share | $6.12 | Diluted [SEP]\n[row 13]: Shares used in calculation of earnings per share | 906,963 | Basic [SEP]\n[row 14]: Shares used in calculation of earnings per share | 911,681 | Diluted [SEP]"]